The present invention generally relates to implantable devices and systems, and associated methods for delivering therapy to nerve structures using components implanted within the vasculature.
Heart failure (HF) is a condition characterized by reduced cardiac output that triggers neurohormonal activation. This compensatory mechanism functions acutely to increase cardiac output and restore left ventricular (LV) functional capacity such that patients remain asymptomatic. Over time, however, sustained activation of these neurohormonal systems triggers pathologic LV remodeling and end-organ damage that ultimately drives the progression of HF.
In many people, persistent hypertension is the predominant contributing actor for development of HF. Management of hypertension can slow or prevent the natural evolution of HF.
The human body maintains blood pressure through the use of a central control mechanism located in the brain with numerous peripheral blood pressure sensing components. These components are generally made of specialized cells embedded in the walls of blood vessels that create action potentials at an increased rate as the cell is stretched. These groups of cells are generally referred to as baroreceptors. The action potentials are propagated back to the central control center via neural pathways along afferent nerves. While there are many baroreceptor components located throughout the body, there are several that are particularly important. Possibly the most important baroreceptor region is located near the bifurcation of the common carotid artery into the internal and external carotid. In this area there is a small enlargement of the vessel tissues, referred to as the carotid bulb or carotid sinus. The carotid baroreceptors are generally found throughout this area. The carotid baroreceptors and related neural pathways form the primary pressure sensing component that provides signals to the brain for regulating cranial and systemic blood pressure.
Applicant's prior Application Publication No. U.S. 2007/0255379, which is incorporated herein by reference, discloses an intravascular neurostimulation device (such as a pulse generator) and associated methods for using the neurostimulation device to stimulate nervous system targets. As discussed in that application, targeting stimulation to baroreceptor afferents in HF patients can lead to decreases in sympathetic tone, peripheral vascular resistance, and afterload. Such stimulation can be used to control blood pressure as a treatment for hypertension or HF. Stimulation of the vagus nerve (e.g. vagal efferents) is known to cause a reduction in heart rate.
The present disclosure describes an implementation of Applicants' previously-disclosed intravascular systems and methods for use in stimulating nervous system targets such as the vagus nerve and/or its branches, the carotid artery, the carotid sinus nerve and/or its branches, baroreceptors, and/or for otherwise activating a baroreceptor response. Systems and methods of the type disclosed may be used for controlling heart rate and/or regulating blood pressure for treatment of hypertension, congestive heart failure or other conditions.
The internal jugular vein, vagus nerve, and common carotid artery (which includes the carotid sinus) are located within the carotid sheath, a fascial compartment within the neck. The carotid sheath provides relatively fixed geometric relationships between these structures while also giving some degree of insulation from surrounding tissue. According to one embodiment disclosed herein, a method is disclosed for transvascularly stimulating contents of the carotid sheath. The method includes advancing an energy delivery element, which may be an electrode, into an internal jugular vein, retaining the energy delivery element in a portion of the internal jugular vein contained within a carotid sheath, and energizing the energy delivery element to transvenously direct energy to target contents of the carotid sheath external to the internal jugular vein. The energy may be directed to a carotid artery within the carotid sinus sheath, and/or to a carotid sinus nerve or nerve branch within the carotid sinus sheath, to nerve branches emanating from carotid artery baroreceptors, and/or to a vagus nerve or nerve branch within the carotid sinus sheath.
In some of the disclosed embodiments, a second electrode or other second energy delivery element is introduced into a second internal jugular vein and retained in a portion of the second internal jugular vein contained within a second carotid sheath. The second energy delivery element is energized to direct energy to contents of the second carotid sheath external to the second internal jugular vein.
Shielding may be used to minimize collateral stimulation of unintended targets. In one embodiment, a shield is positioned at least partially surrounding the carotid sinus sheath. The shield blocks conduction of energy beyond the sheath during energization of the energy delivery element. In another embodiment, an insulative material is delivered into extravascular space adjacent to the internal jugular vein. The insulative material defines a channel within the extravascular space. Energizing the energy delivery, implant causes energy to conduct along the channel to the target contents of the sheath.
In some embodiments, the system my include a plurality of electrodes disposed on the lead, the electrodes including a first array and a second array, wherein the first and second arrays are positioned such that when the first array is positioned in the internal jugular vein to direct stimulation energy transvascularly to a vagus nerve in the carotid sheath, the second array is positioned to direct stimulation energy transvascularly towards a carotid artery or carotid sinus nerve/nerve branch within the carotid sheath. In other embodiments, the same array of electrodes delivers stimulus to each of the target structures within the carotid sheath.
The baroreceptors in the aorta are the second best understood baroreceptors and are also a powerful localized blood pressure sensing component. The aortic baroreceptors are also responsible for providing signals to the brain for regulating system/peripheral blood pressure. Some of the embodiments disclosed herein are positioned to transvascularly deliver energy to these baroreceptors and/or associated nerve structures as an alternative means for neurohormonal control.
Referring to
The lead 14 is intravascularly positioned such that electrodes are oriented to stimulate nervous system structures outside the vessel within which the electrodes are placed. In the embodiment shown in
Referring to
In some embodiments, electrodes are intravascularly positioned to stimulate multiple neurological targets. For example, electrodes positioned in the internal jugular for stimulation of carotid sinus nerve targets (e.g. the carotid sinus nerves or associated baroreceptors) may also be used to additionally stimulate the vagus nerve.
As illustrated in
The system operates to stimulate both the vagus nerve and carotid sinus nerve targets using electrodes on the IJ lead. Stimulation of each such structure may be achieved using the same set of electrodes 18a (
Stimulating the contents of the carotid sheath S can counteract compensatory mechanisms that drive disease progression in chronic HF. Specifically, such stimulation may be used to reduce sympathetic activation and enhance sympathetic tone, and to improve hemodynamics (peripheral vascular resistance, afterload, cycle length and stroke volume) to reduce blood pressure and heart rate.
The electrodes 18a may be positioned to extend both longitudinally (
Therapeutic activation of these structures will provide multiple benefits, including 1) activation of the baro-response to lower blood pressure, 2) activation of the parasympathetic afferent and efferent pathways to help rebalance the sympathetic/parasympathetic imbalance that is common in heart failure patients, 3) mild reduction in heart rate (through vagal stimulation) that can reduce total cardiac energy consumption, reduce diastolic pressures, reduce mean arterial pressures, and possibly reduce afterload.
In a modification to the
In one exemplary arrangement shown in
In an alternative embodiment, the arrays of electrodes may be positioned on an expandable stent-like anchor of the type described below in connection with
In another alternative shown in
Further alternatives to the
In another embodiment, electrodes anchored in the pulmonary artery may be used to simulate neurological targets associated with baroreceptors of the aortic arch. Such targets can include the baroreceptors themselves or the associated nerves. As discussed in the Background section, the aortic baroreceptors are a powerful localized blood pressure sensing component and are also responsible for providing signals to the brain for regulating systemic/peripheral blood pressure. The present embodiment takes advantage of the positional relationship between the aortic arch and the pulmonary artery to position electrodes for stimulation of the aortic baroreceptors. In the human anatomy, the aortic arch crosses the pulmonary artery above the pulmonary artery bifurcation. At this point the pulmonary artery and the aortic artery are in intimate contact. The aortic baroreceptors are co-located at this point. All of these structures are co-located within the thoracic cavity and remain in a relatively fixed geometric relationship. The following embodiment utilizes a single neurostimulation delivery device for stimulating the aortic arch and activating a baro response for blood pressure control in the treatment of hypertension or congestive heart failure.
In a preferred configuration for implementing this embodiment, a single intravascular lead is delivered to the site of the pulmonary artery/aortic arch intersection point. The lead is anchored in the pulmonary artery at this location no as to position the electrodes for optimal stimulation of the aortic arch baroreceptors, while simultaneously preventing the stimulation of other structures in the chest cavity.
Alternatives to the
The embodiment of
Referring to
Referring to
In an alternate embodiment shown in
In the
In any of the exemplary electrode/lead configurations, stimulation may be performed using the same energy delivery protocols for both aortic arch baroreceptor stimulation and vagus nerve stimulation. Alternatively, any of the lead/electrode configurations might utilize separate energy delivery protocols for stimulating the aortic arch baroreceptors and vagal nerve. Several ways in which this could be accomplished include: (a) interleaving/multiplexing (time sequencing where “A” therapy is on for a pre-determined or adaptively determined duration followed by a “B” therapy that is on for a predetermined or adaptively determined time in a repeating “A”/“B” sequence) the delivery of two separate electrical stimulation protocols utilizing the same stimulation electrodes or (b) having a multiplicity of electrodes on the lead such that one set of electrodes can be utilized to uniquely stimulate the carotid baro-response and a second set of electrodes can be utilized to uniquely stimulate the vagus nerve, these therapies would be independent of each other so could be delivered simultaneously but could also be sequenced as described in (a).
The therapy performed using the configurations of
The electrodes may be configured in a uni-polar, bipolar, tri-polar arrangement, or they may be arranged in an array for selective activation. Various configurations for anchoring or supporting the electrodes and lead may be implemented.
Referring to
In another embodiment, a polymeric stent or non-conductive braid may be provided with electrodes mounted to it such that the electrodes are positioned in contact with the vessel wall when the stent or braid is expanded. For example, as shown in
In a modification to the
Alternative embodiments use structures other than stents or braids to support the electrodes against the vessel walls. For example,
In another alternative embodiment shown in
In another embodiment of an electrode anchor device shown in
In an alternate embodiment, the electrodes may instead be formed onto or attached to one face of the member 63.
The anchor 64a is comprised of one or more resilient elements 67 extending laterally from the member 63. The resilient elements are preferably curved so as to extend partly or fully circumferentially along the vessel wall. In the illustrated embodiment, nitinol wires are shaped to include a plurality of v-shaped hoop sections defining the resilient elements 67, with each member curving outwardly from its origination at the substrate and then curving inwardly to give the member a partially circumferential shape. Two such wires are shown, each defining three opposed elements 67. In other embodiments, each element may be discrete from the other elements. In still other embodiments, the elements may be more fully circumferential (e.g. hoops of the type shown in
As illustrated in
These embodiments are shown and described with respect to electrical leads for use in delivering electrical stimulation to nervous system targets as discussed above, or to tissue of the heart, using electrodes. However it is to be understood that these concepts may be used for leads that take the form of fluid conduits for delivery of therapeutic or diagnostic agents. In still other embodiments, the leads may be used for communication of signals representing parameters sensed within the vasculature using sensors on the leads.
Referring to
Lead 116 includes an elongate cable 122 which houses conductors 124a-c that are electrically coupled to the electrodes 120a-c. A member 126 formed of flexible substrate (e.g. silicone) encapsulates the distal portions of the conductors 124a-c and partially encapsulates the electrodes 120a-c, leaving exposed faces 132 on one side of the member 126. The electrodes are provided with pass through lumens 134 which allow the conductors 124a, 124b to be routed through electrodes rather than routed around them.
In an alternate embodiment, the electrodes may instead be formed onto or attached to one face of the member 126.
Anchor 114 is preferably an expandable device radially compressible into a collapsed position for loading into a deployment sleeve for intravascular introduction into a target blood vessel. The device is radially expandable upon release from the deployment sleeve, so that it can expand into contact with the wall of the blood vessel W a target site. The anchor has structural features that allow it to radially engage the vessel wall using forces sufficient to maintain the positioning of the anchor at the target site, but not necessarily sufficient to perform the functions of a stent. The anchor might be a tubular band, sleeve, mesh, braid, laser cut tube, or other framework formed of one or more shape memory (e.g. nickel titanium alloy, thermally activated shape-memory material, or shape memory polymer) elements or stainless steel, Elgiloy, or MP35N elements.
The anchor 114 includes a receiver 136 positioned to receive the member 126 so that the electrodes supported by the member are retained at a desired position within a blood vessel. In the embodiment shown in
The hoops 134 may be individual hoops positionable in a spaced apart arrangement within the blood vessel. In the
In other embodiments all of the hoops, or each of the proximal and distal groupings of the hoops, may be coupled together by struts, a sleeve, or other elements made from polymeric material, ePTFE, or other suitable materials. In the embodiment shown in
To deploy the system 100, the anchor 114 is radially compressed into a collapsed position and loaded into a deployment sleeve. Using known techniques, the deployment sleeve is percutaneously introduced into the vasculature and advanced to the target blood vessel where the electrodes are to be anchored. The anchor 114 is released from the deployment sleeve and allowed to expand within the vessel. Where the anchor 114 is comprised of separate hoops, the anchor may be released in sequential steps in which a distalmost one of the hoops 134 is pushed from the deployment sleeve, and the deployment sleeve is then withdrawn slightly. The next one of the hoops 134 is pushed from the deployment sleeve into the vessel, and the process is repeated for each of the hoops. The amount by which the deployment sleeve is withdrawn after each hoop is released determines the spacing between the hoops.
Once the anchor 114 is deployed, the member 126 is advanced into the receiver 136 as indicated by arrow A1 in
At times it may be necessary to remove the lead from the anchor. For example, lead removal might be desirable if the electronic device energizing the electrode is no longer in use, or because the lead is not functioning properly and should be replaced.
A guidewire is passed through the retrieval catheter and into the receiver 136 within which the distal portion of the lead (at member 126) is disposed. The retrieval catheter is held in place while the lead 116 is withdrawn into it using tension applied to the proximal end of the lead 116.
If a new lead is to be introduced into the receiver 136, the old lead may be fully withdrawn from the retrieval catheter and out of the body, leaving the catheter in place for use in providing a passage for the new lead into the vessel. Alternatively, the retrieval catheter with the old lead inside it may be withdrawn from the body, leaving the guidewire in place. A second catheter is advanced over the guidewire and (optionally) docked to the anchor as described above. The replacement lead is advanced distally through the catheter and inserted into the receiver 136.
In an alternate arrangement, the member 126 of the lead 116 is provided with an opening that may be threaded over the guidewire, allowing the lead 116 to be tracked over the wire into the receiver 136. The opening may be a bore formed in the material of the member, or it may be a loop of suture or other material that is coupled to the member.
The elongate member is mounted to or formed on the anchor, such as on the inner or outer wall of the anchor. It is preferably inwardly recessed from the radially outermost boundary of the anchor (as with the receiver 136 of the first embodiment) so that the exposed surfaces 132 will be generally flush with or inset from the exterior of the anchor when the anchor and lead are implanted. However in other embodiments, the configuration may be such that the exposed surface are positioned radially outwardly of the exterior surface of the anchor. The anchor 114a may take any of the forms disclosed above. The member 126 is insertable into and removable from the receiver 146 as described above, allowing explantation and or replacement of the lead white the anchor remains in the vessel.
In the disclosed embodiments, optimal stimulation results are achieved when the electrodes are positioned to direct the stimulation energy towards the neurological target while minimizing conduction of the energy to unintended targets. As shown in
The injected material forms or defines a channel 80 between the jugular and the carotid artery. The channel provides a conductive path for current passing from the electrode to the region of the carotid artery. In other embodiments, rather than being used to form a channel, the injected materials may be injected onto specifically identified muscles or nerves for which collateral stimulation is undesired. In these embodiments, the injected polymers or other materials form an insulative blanket or cover over the identified muscles or nerves to prevent the electrical stimulation from causing adverse side effects resulting from stimulation of those muscles or nerves.
Fluid substances or materials may alternatively be delivered onto the interior or exterior surface of a vessel containing the stimulation electrodes (e.g. the internal jugular vein) as a way of shielding portions of the vein circumference so that the simulation energy will only conduct through the unshielded portions of the vessel. Such materials may also or alternatively be delivered onto the interior or exterior surface of a vessel other than the vessel containing the electrodes (e.g. a vessel targeted by or in the path of the stimulation energy, such as the carotid artery), in order to limit conduction of stimulation energy beyond a desired region of that vessel.
The delivered materials or substances may be insulative polymers of the type described above, or they may be materials which cause modification of the vessel tissue (e.g. necrosis, ablation) to reduce the conductivity of the vessel tissue in areas through which conduction of stimulation energy is undesirable. Methods for delivering the materials include introducing a catheter 302 to the target site as shown in
In an alternative method, a polymeric material 78 may be delivered onto the exterior surface of the vessel W using a needle 76 passed through the skin as shown in
In another exemplary shielding technique, a minimally invasive surgical technique is used to implant an insulative shield surrounding the exterior wall of vessel W. The shield may be formed of a thin flexible insulative sheet or member positioned on or around the vessel exterior. In one exemplary method for implanting the member shown in
In alternate procedures, such a shield may be implanted through a small incision formed in the skin of the neck and wrapped around fully or partially around the carotid sheath.
For example, a shield 316 may be positioned partially or fully surrounding the carotid sheath S as shown in
Other exemplary shielding methods may include chemical or electrical ablation of nerve or muscle tissue to minimize conduction of electrical stimulation energy to those tissues no as to minimize collateral stimulation effects such as muscle twitches.
Although the majority of this description has been devoted to the use of electrical energy to stimulate the nervous system targets,
White various embodiments of the present invention have been described above, it should be understood that they have been presented by way of example, and not limitation. It will be apparent to persons skilled in the relevant art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention. This is especially true in light of technology and terms within the relevant art(s) that may be later developed. Thus, the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents. The terms “first,” “second” and the like, where used herein, do not denote any order, quantity, or importance. In references to “first blood vessel”, “second blood vessel” etc., the first and second blood vessels may be different blood vessels or they may be the same blood vessel unless otherwise specified.
Any and all patents, patent applications and printed publications referred to above, including patent applications identified for purposes of priority, are incorporated herein by reference.
This application is a continuation of U.S. Ser. No. 12/413,495, filed Mar. 27, 2009, now U.S. Pat. No. 7,925,352 which claims the benefit of U.S. Provisional Application No. 61/039,793, filed Mar. 27, 2008, which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3522811 | Schwartz el al. | Aug 1970 | A |
3645267 | Hagfors | Feb 1972 | A |
3650277 | Sjostrand et al. | Mar 1972 | A |
3835864 | Rasor et al. | Sep 1974 | A |
4573481 | Bullara | Mar 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4881939 | Newman | Nov 1989 | A |
5154172 | Terry, Jr. et al. | Oct 1992 | A |
5170802 | Mehra | Dec 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5199428 | Obel et al. | Apr 1993 | A |
5203326 | Collins | Apr 1993 | A |
5224491 | Mehra | Jul 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5304206 | Baker, Jr. et al. | Apr 1994 | A |
5318592 | Schaldach | Jun 1994 | A |
5330507 | Schwartz et al. | Jul 1994 | A |
5458631 | Xavier | Oct 1995 | A |
5487760 | Villafana | Jan 1996 | A |
5531779 | Dahl et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5607463 | Schwartz et al. | Mar 1997 | A |
5651378 | Matheny et al. | Jul 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5755750 | Petruska et al. | May 1998 | A |
5913876 | Taylor et al. | Jun 1999 | A |
5928272 | Adkins et al. | Jul 1999 | A |
6073048 | Kieval et al. | Jun 2000 | A |
6104956 | Naritoku et al. | Aug 2000 | A |
6141588 | Cox et al. | Oct 2000 | A |
6161047 | King et al. | Dec 2000 | A |
6178349 | Kieval | Jan 2001 | B1 |
6231516 | Keilman et al. | May 2001 | B1 |
6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
6319241 | King et al. | Nov 2001 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6347247 | Dev | Feb 2002 | B1 |
6375666 | Mische | Apr 2002 | B1 |
6393325 | Mann et al. | May 2002 | B1 |
6415187 | Kuzma et al. | Jul 2002 | B1 |
6442413 | Silver | Aug 2002 | B1 |
6445953 | Bulkes et al. | Sep 2002 | B1 |
6449507 | Hill et al. | Sep 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6522926 | Kieval et al. | Feb 2003 | B1 |
6542774 | Hill et al. | Apr 2003 | B2 |
6600954 | Cohen et al. | Jul 2003 | B2 |
6616624 | Kieval | Sep 2003 | B1 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6671556 | Osorio et al. | Dec 2003 | B2 |
6681136 | Schuler et al. | Jan 2004 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6764498 | Mische | Jul 2004 | B2 |
RE38654 | Hill et al. | Nov 2004 | E |
6845267 | Harrison et al. | Jan 2005 | B2 |
RE38705 | Hill et al. | Feb 2005 | E |
6850801 | Kieval et al. | Feb 2005 | B2 |
6865416 | Dev | Mar 2005 | B2 |
6907295 | Gross et al. | Jun 2005 | B2 |
6912419 | Hill et al. | Jun 2005 | B2 |
6934583 | Weinberg et al. | Aug 2005 | B2 |
6957106 | Schuler et al. | Oct 2005 | B2 |
6961618 | Osorio et al. | Nov 2005 | B2 |
6978174 | Gelfand et al. | Dec 2005 | B2 |
6985774 | Kieval et al. | Jan 2006 | B2 |
7076307 | Boveja et al. | Jul 2006 | B2 |
7092753 | Darvish et al. | Aug 2006 | B2 |
7149574 | Yun et al. | Dec 2006 | B2 |
7155279 | Whitehurst et al. | Dec 2006 | B2 |
7155284 | Whitehurst et al. | Dec 2006 | B1 |
7158832 | Kieval et al. | Jan 2007 | B2 |
7162303 | Levin et al. | Jan 2007 | B2 |
7167751 | Whitehurst et al. | Jan 2007 | B1 |
7177702 | Wallace et al. | Feb 2007 | B2 |
7184829 | Hill et al. | Feb 2007 | B2 |
7191012 | Boveja | Mar 2007 | B2 |
7203548 | Whitehurst et al. | Apr 2007 | B2 |
7225019 | Jahns et al. | May 2007 | B2 |
7231260 | Wallace et al. | Jun 2007 | B2 |
7236821 | Cates et al. | Jun 2007 | B2 |
7269457 | Shafer et al. | Sep 2007 | B2 |
7277761 | Shelchuk | Oct 2007 | B2 |
7283875 | Larsson | Oct 2007 | B2 |
7292890 | Whitehurst et al. | Nov 2007 | B2 |
7295881 | Cohen et al. | Nov 2007 | B2 |
7299091 | Barrett et al. | Nov 2007 | B2 |
7300449 | Mische | Nov 2007 | B2 |
7305265 | Fukui | Dec 2007 | B2 |
7321793 | Ben Ezra et al. | Jan 2008 | B2 |
7336997 | Fukui | Feb 2008 | B2 |
7346398 | Gross et al. | Mar 2008 | B2 |
7363076 | Yun et al. | Apr 2008 | B2 |
7363082 | Ransbury et al. | Apr 2008 | B2 |
7366571 | Armstrong | Apr 2008 | B2 |
7389149 | Rossing et al. | Jun 2008 | B2 |
7395119 | Hagen et al. | Jul 2008 | B2 |
7532938 | Machado et al. | May 2009 | B2 |
7561923 | Libbus et al. | Jul 2009 | B2 |
7647101 | Libbus et al. | Jan 2010 | B2 |
7676275 | Farazi et al. | Mar 2010 | B1 |
7756583 | Demarais et al. | Jul 2010 | B2 |
7769446 | Moffitt et al. | Aug 2010 | B2 |
7840278 | Puskas | Nov 2010 | B1 |
7917230 | Bly et al. | Mar 2011 | B2 |
7949409 | Bly et al. | May 2011 | B2 |
7979141 | Caparso et al. | Jul 2011 | B2 |
20020026228 | Schauerte | Feb 2002 | A1 |
20020183791 | Denker et al. | Dec 2002 | A1 |
20030229380 | Adams et al. | Dec 2003 | A1 |
20040010303 | Bolea et al. | Jan 2004 | A1 |
20040019364 | Kieval et al. | Jan 2004 | A1 |
20040024439 | Riso | Feb 2004 | A1 |
20040106954 | Whitehurst et al. | Jun 2004 | A1 |
20040172088 | Knudson et al. | Sep 2004 | A1 |
20040172094 | Cohen et al. | Sep 2004 | A1 |
20040193231 | David et al. | Sep 2004 | A1 |
20040243182 | Cohen et al. | Dec 2004 | A1 |
20040249431 | Williams et al. | Dec 2004 | A1 |
20040254616 | Rossing et al. | Dec 2004 | A1 |
20050010263 | Schauerte | Jan 2005 | A1 |
20050043765 | Williams et al. | Feb 2005 | A1 |
20050049655 | Boveja et al. | Mar 2005 | A1 |
20050070974 | Knudson et al. | Mar 2005 | A1 |
20050131467 | Boveja | Jun 2005 | A1 |
20050131486 | Boveja et al. | Jun 2005 | A1 |
20050137646 | Wallace et al. | Jun 2005 | A1 |
20050143779 | Libbus | Jun 2005 | A1 |
20050149126 | Libbus | Jul 2005 | A1 |
20050149127 | Libbus | Jul 2005 | A1 |
20050149128 | Heil, Jr. et al. | Jul 2005 | A1 |
20050149129 | Libbus et al. | Jul 2005 | A1 |
20050149130 | Libbus | Jul 2005 | A1 |
20050149131 | Libbus et al. | Jul 2005 | A1 |
20050149132 | Libbus | Jul 2005 | A1 |
20050149133 | Libbus et al. | Jul 2005 | A1 |
20050149143 | Libbus et al. | Jul 2005 | A1 |
20050149155 | Scheiner et al. | Jul 2005 | A1 |
20050149156 | Libbus et al. | Jul 2005 | A1 |
20050154437 | Williams et al. | Jul 2005 | A1 |
20050187586 | Cohen et al. | Aug 2005 | A1 |
20050187589 | Wallace et al. | Aug 2005 | A1 |
20050197675 | Cohen et al. | Sep 2005 | A1 |
20050203599 | Garabedian et al. | Sep 2005 | A1 |
20050203600 | Wallace et al. | Sep 2005 | A1 |
20050216070 | Boveja et al. | Sep 2005 | A1 |
20050228459 | Levin et al. | Oct 2005 | A1 |
20050228471 | Williams et al. | Oct 2005 | A1 |
20050234431 | Williams et al. | Oct 2005 | A1 |
20050251216 | Hill et al. | Nov 2005 | A1 |
20050251238 | Wallace et al. | Nov 2005 | A1 |
20050288730 | Deem et al. | Dec 2005 | A1 |
20060009815 | Boveja et al. | Jan 2006 | A1 |
20060015152 | Wallace | Jan 2006 | A1 |
20060025821 | Gelfand et al. | Feb 2006 | A1 |
20060041277 | Deem et al. | Feb 2006 | A1 |
20060041283 | Gelfand et al. | Feb 2006 | A1 |
20060058854 | Abrams et al. | Mar 2006 | A1 |
20060074453 | Kieval et al. | Apr 2006 | A1 |
20060089678 | Shalev et al. | Apr 2006 | A1 |
20060106429 | Libbus et al. | May 2006 | A1 |
20060142801 | Demarais et al. | Jun 2006 | A1 |
20060142802 | Armstrong | Jun 2006 | A1 |
20060195159 | Bradley et al. | Aug 2006 | A1 |
20060212076 | Demarais et al. | Sep 2006 | A1 |
20060212078 | Demarais et al. | Sep 2006 | A1 |
20060224225 | Williams et al. | Oct 2006 | A1 |
20060229677 | Moffitt et al. | Oct 2006 | A1 |
20060235474 | Demarais et al. | Oct 2006 | A1 |
20060247721 | Maschino et al. | Nov 2006 | A1 |
20060253161 | Libbus et al. | Nov 2006 | A1 |
20060259077 | Pardo et al. | Nov 2006 | A1 |
20060259084 | Zhang et al. | Nov 2006 | A1 |
20060259085 | Zhang et al. | Nov 2006 | A1 |
20060265014 | Demarais et al. | Nov 2006 | A1 |
20060265015 | Demarais et al. | Nov 2006 | A1 |
20060271111 | Demarais et al. | Nov 2006 | A1 |
20060276852 | Demarais et al. | Dec 2006 | A1 |
20070027492 | Maschino et al. | Feb 2007 | A1 |
20070027500 | Maschino et al. | Feb 2007 | A1 |
20070038259 | Kieval et al. | Feb 2007 | A1 |
20070043414 | Fifer et al. | Feb 2007 | A1 |
20070255379 | Williams et al. | Feb 2007 | A1 |
20070066957 | Demarais et al. | Mar 2007 | A1 |
20070083239 | Demarais et al. | Apr 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20070129760 | Demarais et al. | Jun 2007 | A1 |
20070135875 | Demarais et al. | Jun 2007 | A1 |
20070156201 | Rossing | Jul 2007 | A1 |
20070167984 | Kieval et al. | Jul 2007 | A1 |
20070173899 | Levin et al. | Jul 2007 | A1 |
20070203549 | Demarais et al. | Aug 2007 | A1 |
20070265687 | Deem et al. | Nov 2007 | A1 |
20080004673 | Rossing et al. | Jan 2008 | A1 |
20080183264 | Bly et al. | Jul 2008 | A1 |
20080183265 | Bly et al. | Jul 2008 | A1 |
20080213331 | Gelfand et al. | Sep 2008 | A1 |
20090171411 | Machado et al. | Jul 2009 | A1 |
20090228078 | Zhang et al. | Sep 2009 | A1 |
20090275997 | Faltys et al. | Nov 2009 | A1 |
20100023088 | Stack et al. | Jan 2010 | A1 |
20100036451 | Hoffer et al. | Feb 2010 | A1 |
20100063564 | Libbus et al. | Mar 2010 | A1 |
Number | Date | Country |
---|---|---|
WO 9216257 | Oct 1992 | WO |
WO 9718856 | May 1997 | WO |
WO 9736637 | Oct 1997 | WO |
WO 03082403 | Oct 2003 | WO |
WO 2004069331 | Aug 2004 | WO |
WO 2006031331 | Mar 2006 | WO |
WO 2006102290 | Sep 2006 | WO |
WO 2006115877 | Oct 2006 | WO |
WO 2007013065 | Feb 2007 | WO |
Entry |
---|
Schwartz et al, Chronic Carotid Sinus Nerve Stimulation in the Treatment of Essential Hypertension, Americal Journal of Surgery, vol. 14, Jul. 1967, pp. 5-15. |
Wanner et al, Transvenous phrenic nerve stimulation in anesthetized dogs, Journal of Applied Physiology, vol. 34, No. 4, Apr. 1973, pp 489, 494. |
Watchko et al, Diaphragmatic Pressure in Piglets: Transvenous versus Direct Phrenic Nerve Stimulation, Pediatric Pulmonology, vol. 2, No. 4, Jul.-Aug 1986, pp. 198-201. |
Thompson et al, Bradycardia induced by intravascular versus direct stimulation of the vagus nerve, Ann. Thorac. Surg., 65:637-42, 1998. |
Zhang Y, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2009; 2:692-699. |
Peters et al, The Evolution Strategy—A Search Strategy Used in Individual Optimization of Electrical Parameters for Therapeutic Carotid Sinus Nerve Stimulation, IEEE Transactions on Biomedical Engineering, vol. 36, No. 7, Jul. 1, 1989. |
Cooper et al, Neural Effects on Sinus Rate and Atrioventricular Conduction Produced by Electrical Stimulation from a Transvenous Electrode Catheter in the Canine Right Pulmonary Artery, Circulation Research, vol. 46, No. 1, Jan. 1980. |
Goldberger et al, New technique for vagal nerve stimulation, Journal of Neuroscience Methods 91, pp. 109-114, 1999. |
Brown et al, Long term bradycardia by electrical pacing: a new method for studying heart rate reduction, Cardiovascular Research, vol. 28, pp. 1774-1779, 1994. |
Coleridge et al, Reflex Effects of Stimulating Baroreceptors in the Pulmonary Artery, J. Physiol, 166, pp. 197-210, 1963. |
Nabutovsky et al, Lead Design and Initial Application of a New Lead for Long-Term Endovascular Vagal Stimulation, Pace vol. 30, Supplement 1, pp. S215-S218, Jan. 2007. |
Li et al, Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats, Circulation , 2004. |
Bilgutay, Vagal Tuning, A new concept in the treatment of supraventricular arrhythmias, angina pectoris, and heart failure, Journal of Thoracic and Cardiovascular Surg., vol. 56, No. 1, pp. 71-82, Jul. 1968. |
Communication from European Patent Office relating to corresponding European Application No. EP 07 763 673.6, attaching PCT Written Opinion for PCT/US2007/002932. |
PCT Search Report for PCT/US2007/002932. |
Number | Date | Country | |
---|---|---|---|
20110166482 A1 | Jul 2011 | US |
Number | Date | Country | |
---|---|---|---|
61039793 | Mar 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12413495 | Mar 2009 | US |
Child | 13042350 | US |